Kite Pharma (KITE) Posts Q3 Loss of 24c/Share

Kite Pharma (NASDAQ: KITE) reported Q3 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23).

"This has been an exciting quarter for Kite and our collaborators at the National Cancer Institute (NCI), as we continue to make substantial progress with our clinical programs, including our lead product candidate, KTE-C19," said Dr. Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "Clinical data presented this quarter in both The Lancet and The Journal of Clinical Oncology further validate the growing body of support for the role of CAR-T cell immunotherapy in the treatment of B-cell lymphomas and leukemias."

Dr. Belldegrun continued, "We have a busy few months ahead of us, focusing on the achievement of clinical and regulatory milestones as we approach year-end and move into 2015. Additionally, we have oral presentations related to KTE-C19 scheduled to take place at the upcoming American Society of Hematology (ASH) meeting in San Francisco next month."

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c